TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in scores of the Caregiver's Feeding Style Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of aneurysm wall inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of EGFR actionable alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal mucosa cilia (NMC) function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Experiencing Acute Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of all screened participants who were ultimately enrolled
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of enrolled participants who drop out immediately after assignment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Maternal sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of asthma-like episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Hip Outcome Score (iHOT-12)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Pain Score using a visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability of the tDCS treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of the tDCS treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal nasal bone length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Intervention Adherence Rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Completion rate of re-chemotherapy cycles
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Categorized Based on Bleeding Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Categorized by Impact on Daily Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Categorized Based on Disease Management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Transcriptional activity of microbiomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcriptomic profiles of the communities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolites produced and microbial metabolic pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average total (global index) Movement Disorder-Childhood Rating Scale 4-18 Revised (MD-CRS 4-18-R) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average total standardized Caregiver Priorities & Child Health Index of Life with Disabilities (CPCHILD) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Skin Quality Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in sleep onset latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in wake after sleep onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean number of referrals for lung cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean PLCOm2012 risk prediction model score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Orthodontic Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of laceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: sessile serrated lesions miss rate (SSLMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AIH disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corticosteroid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total amount of oxygen consumed per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vulvar Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Enterocyte damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of significant malignancy sites in the prostate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with successful aspiration of portal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients with procedure-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hypotension after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of spontaneous conversion to SR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of early recurrence of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantification of NLRP6 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in menstrual cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Antimicrobial consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days of therapy (DOT)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of therapy (LOT)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Instrumented Timed Up and Go Test (iTUG) (Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State-Trait Anxiety Inventory (STAI) (Change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dizziness Handicap Inventory (DHI) (Change)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinically significant dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief From Premenstrual Cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief From Menstrual Cramps During the Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Usage of OTC NSAIDS
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Monthly Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Score of the Strategies Used by People to Promote Health (SUPPH)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Utility of mindfulness practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Likability of mindfulness practices
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complications Related to Post COVID-19 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants completing the two-week 5 mg dose without discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants completing the two-week 5 mg dose without moderate to severe hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: 20 m Sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete geriatric assessment clinic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction as determined by patient follow-up questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Length of transplant stay in days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Occurrence of Dose Limiting Events
Endpoint domain: Adverse events/effects
Primary endpoint: EEG - event related oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in children's externalizing problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parental autonomy support
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: interincisal distance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tragus-commissura distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lateral canthus-angulus distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distinction between epileptic and non-epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of disease burden after CAR-T Cells treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Migraine Disability Assessment Test - 28 Day Version (MIDAS-28) Scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum Tolerated Dose (MTD) / Recommended Expansion Dose (RED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV prevention effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment of CP101-associated microbes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of CP101
Endpoint domain: Adverse events/effects
Primary endpoint: Steroid-free clinical remission (CDAI < 150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid-free clinical remission (SCCAI < 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine vacuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal change of retinal pigment epithelium defects on Fundus Autofluorescence (FAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal change of retinal pigment epithelium defects on Spectral Domain Optical Coherence Tomography (SD-OCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal change of retinal pigment epithelium defects on infrared imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper trapezius electrical muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in HIV incidence
Endpoint domain: Mortality/survival
Primary endpoint: Change in STI incidence
Endpoint domain: Mortality/survival
Primary endpoint: Changes in adherence to risk-reduction plan
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Quality of life (QOL) at > 3 months post-COVID-19 diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life (QOL) at 12-36 months post first study visit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Effort tolerance as measured by a 6-minute walk test at > 3 months post-COVID-19 diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores from cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage Change in generalized tonic-clonic (PGTC) seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: SWAL-QOL Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety and tolerability of CTX-8371
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Survival (OS) in AR LBD Mutation-Positive Participants
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) in AR LBD Mutation-Negative Participants
Endpoint domain: Mortality/survival
Primary endpoint: Radiographic Progression-free Survival (rPFS) in AR LBD Mutation-Positive Participants
Endpoint domain: Mortality/survival
Primary endpoint: Radiographic Progression-free Survival (rPFS) in AR LBD Mutation-Negative Participants
Endpoint domain: Mortality/survival
Primary endpoint: Repetitive Behavior Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in health utilisation cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Systemic Clinical Outcome and Routine Evaluation - 15 items version (SCORE-15)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Kerns Security Scale-Revised 21
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quadricep Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thigh muscles composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Transdermal estimates of alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transdermal estimates of drinking risk level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transdermal estimates of blood alcohol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Acute treatment tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic treatment tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Average blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knee extension strength change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain at wrist joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist Range of Movement at wrist joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Ability at wrist joint
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximum urinary flow rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Best end-expiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful inflation of the gastric balloon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with moderate to major postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with major postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Oxygene Level Dependent (BOLD) MRI signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at group sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant satisfaction ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mortality of patients with septic shock
Endpoint domain: Mortality/survival
Primary endpoint: KOOS-PF Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Universal Goniometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Good ON-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual participant variability for ON-time without troublesome dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of valid PD Diaries
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent change from baseline in fasting serum TG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute change from baseline in glycated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximal inspiratory mouth pressure (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Mean Pleasantness Rating of Gentle Brushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mechanical Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Temporal Summation of Pinprick Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cigarettes smoked per day (CPD)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Biochemically-confirmed 7-day point-prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects successfully receiving the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ultrasound/Controlled Attenuation Parameters (UAP/CAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Edmonton Symptom Diagnosis Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from European Association for Cancer Research and Treatment BR23 Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Bleeding Episodes Treated with rVWF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Surgical Procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with Surgery Outcomes (Success, Failure, Complications)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Conversion of Acetate to Glutamate + Glutamine (Glx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of [2H]Glx in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate at which program was accepted, measured by attendance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants Achieving Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune cell profile (composition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: wound proteome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: wound microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of thrombotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children cured at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children prescribed an antibiotic at initial consultation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardiovascular fitness (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Any stroke or death within 30 days of enrollment or any revascularization procedure OR an ischemic stroke in the territory of the symptomatic intracranial artery between 31 day to 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Severe or moderate bleeding (GUSTO score)
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of Binge Eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left ventricular diastolic reserve (Δe')
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BAT detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes